Paul Weiss is a Managing Director of Venture Investors Health Fund and is located in Madison, Wisconsin. Paul joined Venture Investors in 2006, bringing 20-plus years of operating experience in the biotech and pharmaceutical industries. Paul leverages this experience by focusing on investment prospects in biopharma, diagnostics, and devices when there is overlap with biopharma.
Paul serves on the Board of Directors of Invenra, Iterion Therapeutics, FluGen, and Madison Vaccines. He is a former board member and current shareholder representative of Neurovance (spun out of Euthymics and sold to Otsuka for up to $1 billion), Aerpio Pharmaceuticals (spun out of Akebia, NASDAQ:ARPO, now Aadi Bioscience, NASDAQ:AADI), Akebia Therapeutics (NASDAQ:AKBA), and Tissue Regeneration Systems.
Prior to joining Venture Investors, Paul served as President of the Gala Biotech business unit of Cardinal Health (now the biologics division of Catalent Pharma Solutions), a division that was established when the Venture Investors portfolio company, Gala Design, Inc., under his leadership as CEO was acquired by Cardinal Health. Prior to joining Gala, Paul served as VP of Business Development of 3-Dimensional Pharmaceuticals, a venture capital backed biotechnology company with a drug discovery platform that successfully completed an IPO during his tenure with the company and was subsequently acquired by Johnson & Johnson. Prior to that, Paul worked as Director of Licensing for Wyeth-Ayerst (now part of Pfizer).
In his spare time, Paul enjoys spending time with family, learning more about wine, including donating and helping with various non-profit fundraising events, and working with community out-reach programs in the environmental and education areas.